Marinus Pharmaceuticals, Inc. (MRNS)

NASDAQ: MRNS · IEX Real-Time Price · USD
1.470
+0.040 (2.80%)
Jul 22, 2024, 2:19 PM EDT - Market open
2.80%
Market Cap 80.74M
Revenue (ttm) 28.29M
Net Income (ttm) -145.34M
Shares Out 54.93M
EPS (ttm) -2.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 350,059
Open 1.430
Previous Close 1.430
Day's Range 1.425 - 1.480
52-Week Range 1.100 - 11.260
Beta 1.13
Analysts Buy
Price Target 10.86 (+638.78%)
Earnings Date Aug 8, 2024

About MRNS

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABA... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 166
Stock Exchange NASDAQ
Ticker Symbol MRNS
Full Company Profile

Financial Performance

In 2023, MRNS's revenue was $30.99 million, an increase of 21.63% compared to the previous year's $25.48 million. Losses were -$141.41 million, 613.6% more than in 2022.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for MRNS stock is "Buy." The 12-month stock price forecast is $10.86, which is an increase of 638.78% from the latest price.

Price Target
$10.86
(638.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Marinus Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS

NEW YORK, NY / ACCESSWIRE / July 22, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

2 hours ago - Accesswire

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)

Shareholders with losses of $100,000 or more are encouraged to contact the firm. LOS ANGELES, July 22, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming Au...

2 hours ago - GlobeNewsWire

UPCOMING MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmace...

2 hours ago - Accesswire

Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact The Gross Law Firm about pending Class Action - MRNS

NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS).

2 hours ago - GlobeNewsWire

Shareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS

NEW YORK , July 22, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) of a class action securities lawsuit. CLA...

8 hours ago - PRNewsWire

Shareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS

NEW YORK, NY / ACCESSWIRE / July 21, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

1 day ago - Accesswire

UPCOMING MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmace...

1 day ago - Accesswire

Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) - August 5, 2024 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / July 20, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

1 day ago - Accesswire

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. (“Marinus” or the “Company”) (NASDAQ: MRNS). Such i...

2 days ago - GlobeNewsWire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2...

2 days ago - GlobeNewsWire

Marinus Pharmaceuticals Inc Is Being Probed By The Schall Law Firm Which Motivates Affected Investors To Begin Discussions

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceu...

2 days ago - Accesswire

Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS

NEW YORK, NY / ACCESSWIRE / July 19, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

3 days ago - Accesswire

Contact Levi & Korsinsky by August 5, 2024 Deadline to Join Class Action Against Marinus Pharmaceuticals, Inc. (MRNS)

NEW YORK, NY / ACCESSWIRE / July 19, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

3 days ago - Accesswire

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on August 5, 2024 in Marinus Lawsuit

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Marinus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Marinu...

3 days ago - PRNewsWire

Levi & Korsinsky Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 – MRNS

NEW YORK, NY / ACCESSWIRE / July 18, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

3 days ago - Accesswire

MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK , July 18, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021...

3 days ago - PRNewsWire

Contact Levi & Korsinsky by August 5, 2024 Deadline to Join Class Action Against Marinus Pharmaceuticals, Inc.(MRNS)

NEW YORK, NY / ACCESSWIRE / July 18, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

3 days ago - Accesswire

Marinus Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm Which Urges Impacted Investors To Initiate Conversations

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceu...

3 days ago - Accesswire

Shareholders that lost money on Marinus Pharmaceuticals, Inc. (MRNS) should contact Levi & Korsinsky about pending Class Action - MRNS

NEW YORK, NY / ACCESSWIRE / July 18, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

3 days ago - Accesswire

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 5, 2024 in Marinus Pharmaceuticals, Inc. Lawsuit - MRNS

NEW YORK, NY / ACCESSWIRE / July 18, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

4 days ago - Accesswire

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 5, 2024 in Marinus Lawsuit - MRNS

NEW YORK, NY / ACCESSWIRE / July 18, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

4 days ago - Accesswire

Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS

NEW YORK, NY / ACCESSWIRE / July 18, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

4 days ago - Accesswire

Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...

4 days ago - Business Wire

The Schall Law Firm Starts An Investigation Into Marinus Pharmaceuticals Inc And Encourages Affected Investors To Begin Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceu...

4 days ago - Accesswire

Marinus Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 – MRNS

NEW YORK, NY / ACCESSWIRE / July 17, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securit...

4 days ago - Accesswire